In NSCLC, oncogenic driver mutations are commonly found in genes such as epidermal growth factor receptor (EGFR), erb‐b2 receptor tyrosine kinase 2 (HER2), v‐raf murine sarcoma viral oncogene homolog B1 (BRAF), Kirsten rat sarcoma viral oncogene homolog (KRAS), anaplastic lymphoma kinase (ALK), ROS proto‐oncogene 1 (ROS1), RET proto‐oncogene (RET), and hepatocyte growth factor receptor (MET) [2]. This evidence concerns the gene ALK and non-small cell lung carcinoma.